
CASE REPORT FOR TWO SIBLINGS CARRYING
NEUROFIBROMATOSIS TYPE 1 WITH A RARE
NF1: c.5392C>T MUTATION Sayın Kocakap DB1,*, Gündüz Ö2
, Özer L3
, Durak M *Corresponding Author: : Associate Professor Derya B. Sayın Kocakap, Kırıkkale Üniversitesi Tıp
FakültesiTıbbi GenetikAD,AnkaraYolu 7.km, 71450, Kırıkkale,Turkey.Tel.: +90-318-357-3300/5784.
Fax: +90-318-225-2819. E-mail: dsayin@yahoo.com page: 0
|
DISCUSSION
The NF1 gene spans 287 kb of chromosome 17q11.2
and comprises 57 constitutive and four alternatively spliced
exons (9a,10a-2, 23a and 48a) [7]. To date, the Human
Gene Mutation Database has documented more than 2450
disease-causing NF1 variants, of which 745 are missense/
nonsense [8]. In the Varsome database (https:// vas=rsome.
com/gene/nf1), 26.1% of reported class 1 NF1 variants
(328/1254) are nonsense mutations [9]. In our analysis, a
C>T transition at nucleotide 5392 in exon 38, causing a
premature termination codon at codon 1798 instead of a
glutamine codon, was detected.
Recently, Zhu et al. [10] reported a study of NF1
germline variantsin patients with congenital pseudoarthrosis of the tibia (CPT). Screening 55 NF1 patients with CPT
they found 44 NF1 variants, of which 25 were novel. They
described a c.5392C>T, p.(Gln1798Ter) inherited mutation in one patient, but they did not present the patient’s
clinical characteristics [10].
Here, we present two cases of NF1, a brother and a
sister with c.5392C>T, p.Gln1798Ter mutation on the NF1
gene. Neurofibromatosistype 1 has great clinical variability
even between affected individuals of the same family with the same mutation. Our represented cases of siblings also
show inter-individual variation; they have differentfeatures
ofskin pigmentation, and the sister has an additional neural
sheath tumor. The prominent lesions of the brother were
relatively benign café au lait macules, but the sister also had
a plexiform neurofibroma, estimated to have a lifetime risk
of 5.0% for malignant transformation [11]. We speculate
that modifier genes, as well as epigenetic and environmental changes, might be the cause of the clinical variability.
Although NF1 is a monogenic disorder, its clinical
variability is similar to multifactorial disorders and may
be affected by epigenetic and environmental changes,
modifier genes as well as second somatic mutations during tumorigenesis. As NF1 is expressed in a large variety
of tissues, possible modifier genes have variable effects,
such as actin cytoskeleton remodeling, cell signaling, intracellular trafficking, ubiquitylation, membrane localization, cell adhesion and neural differentiation [12]. In twin
studies, it has been shown that plexiform neurofibromas
tended to be less concordant, and it is explained by the
two-hit hypothesis as many NF1-related tumors necessitate a second mutation on the wild-type NF1 allele [13].
Consistent with this view, the major phenotypic difference
is plexiform neurofibroma between our cases. To the best of our knowledge, this is the first case
report with detailed clinical findings of NF1 with NF1:
c.5392C>T mutation.Although NF1: c.5392C>T is a nonsense mutation, predicted to cause premature termination
and a truncated neurofibromin protein, the clinical course
of NF1 in our patients and their family is benign. Even
though there is great intra-familial and inter-familial variability in NF1 phenotypes, we can speculate that with the
effect of epigenetic and environmental changes and modifier genes, the NF1: c.5392C>T mutation did not cause a
severe NF1 phenotype in this family.
Declaration of Interest. The authors report no conflicts of interest. The authors alone are responsible for the
content and writing of this article.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|